SCHEMBL3871503

SCHEMBL3871503

NC(=O)CN[C@H]1C[C@H]2CC[C@@H](C1)N2Cc1ccc(Cl)cc1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 4/20 0.52
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51
MAPT P10636 1/20 0.48
MAPK1 P28482 1/20 0.48
CXCR6 O00574 1/20 0.47
OPRK1 P41145 2/20 0.46
OPRM1 P35372 1/20 0.46
OPRD1 P41143 1/20 0.46
KCNH2 Q12809 1/20 0.46
ARG1 P05089 1/20 0.46
ARG2 P78540 1/20 0.46
JAK2 O60674 1/20 0.45
JAK1 P23458 1/20 0.45
TYK2 P29597 1/20 0.45
JAK3 P52333 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.44
LMNA P02545 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3871504 0.79 MEN1 (0.57) LTA4HMEN1KMT2AMAPTMAPK1
SCHEMBL13853081 0.79 MEN1 (0.57) LTA4HMEN1KMT2AMAPTMAPK1
SCHEMBL3870324 0.78 KMT2A (0.51) LTA4HMEN1KMT2AMAPTMAPK1
SCHEMBL3870321 0.78 KMT2A (0.51) LTA4HMEN1KMT2AMAPTMAPK1
SCHEMBL3869200 0.77 MEN1 (0.59) LTA4HMEN1KMT2AMAPTMAPK1
SCHEMBL3869202 0.77 MEN1 (0.59) LTA4HMEN1KMT2AMAPTMAPK1
SCHEMBL3874225 0.76 MAPT (0.57) LTA4HMEN1KMT2AMAPTMAPK1
SCHEMBL3874227 0.76 MAPT (0.57) LTA4HMEN1KMT2AMAPTMAPK1
SCHEMBL3874160 0.75 KMT2A (0.56) LTA4HMEN1KMT2AMAPTMAPK1
SCHEMBL3874162 0.75 KMT2A (0.56) LTA4HMEN1KMT2AMAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1891064-B1 N-AMIDE DERIVATIVES OF 8-AZABICYCLO[3.2.1]OCT-3-YL AS CCR1 ANTAGONISTS ALMIRALL SA (ES) 2009-09-02 EP disclosed
US-20090130090-A1 N-amide Derivatives of 8-Azabicyclo[3.2.1]OCT-3-YL AS CCR1 Antagonists LABORATORIOS ALMIRALL, S.A. (ES) 2009-05-21 US disclosed
EP-1891064-A1 N-AMIDE DERIVATIVES OF 8-AZABICYCLO[3.2.1]OCT-3-YL AS CCR1 ANTAGONISTS Laboratorios Almirall, S.A. (ES) 2008-02-27 EP disclosed
WO-2006133802-A1 N-AMIDE DERIVATIVES OF 8-AZABICYCLO[3.2.1]OCT-3-YL AS CCR1 ANTAGONISTS LABORATORIOS ALMIRALL, S.A. (ES) 2006-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090130090-A1 N-amide Derivatives of 8-Azabicyclo[3.2.1]OCT-3-YL AS CCR1 Antagonists CCR1, CCR3, CCR8 LTA4H 647/4885MEN1 4445/4885KMT2A 2987/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.